These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12639564)

  • 1. Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides.
    Palani A; Shapiro S; Clader JW; Greenlee WJ; Vice S; McCombie S; Cox K; Strizki J; Baroudy BM
    Bioorg Med Chem Lett; 2003 Feb; 13(4):709-12. PubMed ID: 12639564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
    Palani A; Shapiro S; Josien H; Bara T; Clader JW; Greenlee WJ; Cox K; Strizki JM; Baroudy BM
    J Med Chem; 2002 Jul; 45(14):3143-60. PubMed ID: 12086500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives.
    Imamura S; Ishihara Y; Hattori T; Kurasawa O; Matsushita Y; Sugihara Y; Kanzaki N; Iizawa Y; Baba M; Hashiguchi S
    Chem Pharm Bull (Tokyo); 2004 Jan; 52(1):63-73. PubMed ID: 14709870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
    Palani A; Shapiro S; Clader JW; Greenlee WJ; Cox K; Strizki J; Endres M; Baroudy BM
    J Med Chem; 2001 Oct; 44(21):3339-42. PubMed ID: 11585437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.
    Palani A; Shapiro S; Clader JW; Greenlee WJ; Blythin D; Cox K; Wagner NE; Strizki J; Baroudy BM; Dan N
    Bioorg Med Chem Lett; 2003 Feb; 13(4):705-8. PubMed ID: 12639563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design and discovery of novel amide CCR5 antagonists.
    Pryde DC; Corless M; Fenwick DR; Mason HJ; Stammen BC; Stephenson PT; Ellis D; Bachelor D; Gordon D; Barber CG; Wood A; Middleton DS; Blakemore DC; Parsons GC; Eastwood R; Platts MY; Statham K; Paradowski KA; Burt C; Klute W
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1084-8. PubMed ID: 19167884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
    Skerlj R; Bridger G; Zhou Y; Bourque E; Langille J; Di Fluri M; Bogucki D; Yang W; Li T; Wang L; Nan S; Baird I; Metz M; Darkes M; Labrecque J; Lau G; Fricker S; Huskens D; Schols D
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2450-5. PubMed ID: 21398122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
    Strizki JM; Xu S; Wagner NE; Wojcik L; Liu J; Hou Y; Endres M; Palani A; Shapiro S; Clader JW; Greenlee WJ; Tagat JR; McCombie S; Cox K; Fawzi AB; Chou CC; Pugliese-Sivo C; Davies L; Moreno ME; Ho DD; Trkola A; Stoddart CA; Moore JP; Reyes GR; Baroudy BM
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12718-23. PubMed ID: 11606733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.
    McCombie SW; Tagat JR; Vice SF; Lin SI; Steensma R; Palani A; Neustadt BR; Baroudy BM; Strizki JM; Endres M; Cox K; Dan N; Chou CC
    Bioorg Med Chem Lett; 2003 Feb; 13(3):567-71. PubMed ID: 12565973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.
    Tagat JR; Steensma RW; McCombie SW; Nazareno DV; Lin SI; Neustadt BR; Cox K; Xu S; Wojcik L; Murray MG; Vantuno N; Baroudy BM; Strizki JM
    J Med Chem; 2001 Oct; 44(21):3343-6. PubMed ID: 11585438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
    Skerlj R; Bridger G; Zhou Y; Bourque E; McEachern E; Langille J; Harwig C; Veale D; Yang W; Li T; Zhu Y; Bey M; Baird I; Sartori M; Metz M; Mosi R; Nelson K; Bodart V; Wong R; Fricker S; Mac Farland R; Huskens D; Schols D
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6950-4. PubMed ID: 22033460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
    Shiraishi M; Aramaki Y; Seto M; Imoto H; Nishikawa Y; Kanzaki N; Okamoto M; Sawada H; Nishimura O; Baba M; Fujino M
    J Med Chem; 2000 May; 43(10):2049-63. PubMed ID: 10821717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
    Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
    Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.
    Watson C; Jenkinson S; Kazmierski W; Kenakin T
    Mol Pharmacol; 2005 Apr; 67(4):1268-82. PubMed ID: 15644495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.
    Finke PE; Oates B; Mills SG; MacCoss M; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Carella A; Carver G; Holmes K; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Schleif WA; Emini EA
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2475-9. PubMed ID: 11549450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.
    Shen DM; Shu M; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):935-9. PubMed ID: 15012997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile synthesis of 4-substituted-4-aminopiperidine derivatives, the key building block of piperazine-based CCR5 antagonists.
    Jiang XH; Song YL; Long YQ
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3675-8. PubMed ID: 15203141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
    Tagat JR; McCombie SW; Nazareno D; Labroli MA; Xiao Y; Steensma RW; Strizki JM; Baroudy BM; Cox K; Lachowicz J; Varty G; Watkins R
    J Med Chem; 2004 May; 47(10):2405-8. PubMed ID: 15115380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agents.
    Yeung KS; Qiu Z; Xue Q; Fang H; Yang Z; Zadjura L; D'Arienzo CJ; Eggers BJ; Riccardi K; Shi PY; Gong YF; Browning MR; Gao Q; Hansel S; Santone K; Lin PF; Meanwell NA; Kadow JF
    Bioorg Med Chem Lett; 2013 Jan; 23(1):198-202. PubMed ID: 23200252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.
    Shankaran K; Donnelly KL; Shah SK; Guthikonda RN; MacCoss M; Mills SG; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Carella A; Carver G; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3419-24. PubMed ID: 15177445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.